4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Neurology by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 2987 ongoing clinical trials involving Neurology
Of the 2987 trials,1121 trials are in Phase II
Furthermore, 652 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Neurology by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Neurology, a Central Nervous System disorder. The largest number of ongoing clinical trials for Neurology is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Neurology-related drug trials.

F. Hoffmann-La Roche Ltd: The leading ongoing Neurology related clinical trial sponsor

F. Hoffmann-La Roche Ltd is the top sponsor for Neurology-related ongoing clinical trials.

Biogen Inc, Novartis AG, UCB SA and Eisai Co Ltd are among other notable clinical trial sponsors involved in Neurology. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Neurology

Ocrelizumab (Ocrevus), Eculizumab (Soliris) and Dimethyl fumarate (Tecfidera) are among the key marketed drugs involving Neurology.

Ocrelizumab (Ocrevus) is a humanized monoclonal antibody. It functions via Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20 mechanism of action. Ocrelizumab is formulated as concentrated solution and solution for intravenous route of administration. Ocrelizumab was first approved in 2017 and is marketed globally in the US, UK, Canada, Germany, and France by several prominent pharma giants including Genentech USA Inc.

Eculizumab (Soliris) is a humanized monoclonal antibody directed against terminal complement protein C5. It functions via Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Inhibitor mechanism of action. Eculizumab is formulated as injectable concentrated solution and injectable solution for intravenous route of administration. Eculizumab was first approved in 2007 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Alexion Pharmaceuticals Inc.

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Visit Report Store